A valuable tool used to assess eligibility for weight management therapies, including GLP-1 receptor agonists, is Body Mass Index (BMI)
Current Pharmaceutical Design, 26(29), 35383554
Diabetes Obes Metab 19(4):524536 Husain M, Bain SC, Holst AG, Mark T, Rasmussen S, Lingvay I (2020) Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Research-grade runs 95% or higher
Sources Novo Nordisk: Ozempic Pricing Novo Nordisk: Wegovy Pricing Novo Nordisk: Rybelsus Pricing Healthinsurance.org: Does health insurance cover drugs used for weight loss such as Ozempic, Wegovy, Mounjaro, and Zepbound
Discreet Delivery : Medications are shipped directly to your home